Biological sample management, covering collection, processing, labeling, shipping, storage, chain of custody, analysis, reconciliation and consent tracking, behaves like a separate study running inside your trial. When it fails through hemolyzed samples, temperature excursions, mislabeling or missing consent for future use, it can undermine pharmacokinetic and biomarker endpoints that the whole program depends on.
Why is sample management so risky?
Samples pass through many hands: site staff, couriers, central laboratories, specialty laboratories and biorepositories. Requirements vary by sample type, and some must be processed within tight time windows. International shipments add dangerous goods rules and import permits. And samples may be stored for years, long after the study team that collected them has moved on.
What should a sample management plan include?
Sample types and collection timepoints.
Collection and processing instructions, including timing and equipment.
Kits and labeling conventions.
Shipping logistics, couriers and temperature monitoring.
Chain of custody documentation.
Storage locations, conditions and durations.
Consent tracking for optional samples and future research.
Rules for destruction, including after consent withdrawal.
A reconciliation process across sites, couriers and laboratories.
Data transfers between laboratories, EDC and analysis datasets.
Who should own sample management?
Name a sponsor owner, even in a small company. The CRO, central laboratory and specialty laboratories all play roles, but without a single accountable person, problems fall between them. The owner should be able to answer at any time how many samples are expected, collected, received and analyzed.
Agree, too, on what happens to samples after the study. Storage durations, the conditions under which samples may be used for future research and the process for destruction should be settled in the protocol and consent before collection begins, not negotiated with a biorepository years later.
How do you reconcile samples?
Compare what the visit schedule says should exist with what sites report collecting, what laboratories report receiving and what has been analyzed. Do it regularly, not at the end. Discrepancies are far easier to resolve while the site staff involved still remember the visit.
Why does consent tracking matter so much?
Participants may agree to core samples but decline optional or future research. Some will later withdraw consent. Every one of those choices must be honored, sometimes years later. A sample inventory that cannot be linked to current consent status is both an ethical and a regulatory risk.
How do you help sites get it right?
Clear, visual manuals, practical training and timely feedback. Share sample quality metrics with sites, such as hemolysis rates or late shipments, so they can correct problems early. Sites want to do this well, and simple tools make a large difference.
Have a sample management lesson others should hear? Continue the discussion with me on LinkedIn.
